IBMX 100 mg | 99.76%
TargetMol
IBMX is a pan-phosphodiesterase (PDE) inhibitor (IC50s: 6.5/26.3/31.7 μM for PDE3/PDE4/PDE5).
More Information Supplier PageIBMX
Search Results
Diosmetin 100 mg | 100.00%
TargetMol
Diosmetin
Carvedilol EP IMpurity E 50 mg | Purity Not Available
TargetMol
Carvedilol EP IMpurity E
debutylbupivacaine 200 mg | Purity Not Available
TargetMol
Debutylbupivacaine is the intermediate of ropivacaine hydrochloride and bupivacaine.
More Information Supplier Pagedebutylbupivacaine
7ACC2 1 mg | 100.00%
TargetMol
7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.
More Information Supplier Page7ACC2
7ACC2 25 mg | 100.00%
TargetMol
7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for [14C]-lactate influx; new antitumor treatment targeting lactate transport in Y cells.
More Information Supplier Page7ACC2
Rac-Belinostat 5 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
ZLN005 200 mg | Purity Not Available
TargetMol
ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005
ZLN005 100 mg | Purity Not Available
TargetMol
ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005
ZLN005 25 mg | Purity Not Available
TargetMol
ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005